Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry. METHODS: Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing. RESULTS: gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis. CONCLUSION: Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Kumar, P., Henikoff, S., & Ng, P. C. (2009) · Nature Protocols · doi:10.1038/nprot.2009.86 · Cited by 6,521 · cited 1×
“Pathogenicity of the identified missense variants was assessed using the sorting intolerant from tolerant (SIFT) method.(22) The frequencies of each variant were evaluated using the Exome Aggregation Consortium (ExAC) database (http://exac.”
MethodGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 1×
“A recent analysis revealed that fecal microbial flora is altered in PD, suggesting an environmental change in the large intestine.(36,37) Although constipation and fecal bacterial change are predominantly attributed to large intestine function, caffeine absorption mainly occurs in the small intestine, where bacterial…”
BackgroundA meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease
Hernán, M. A., Takkouche, B., Caamaño‐Isorna, F., & Gestal‐Otero, J. J. (2002) · Annals of Neurology · doi:10.1002/ana.10277 · Cited by 818
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“There have been several reports suggesting an inverse association between daily caffeine consumption and a reduced risk of developing PD in men, and in women not taking hormone replacement therapy.(2,3) Caffeine can protect against nigral neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP)–indu…”
BackgroundThe role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344 · cited 1×
“Although constipation and fecal bacterial change are predominantly attributed to large intestine function, caffeine absorption mainly occurs in the small intestine, where bacterial overgrowth in PD is associated with levodopa malabsorption leading to motor fluctuations.(31,38) Therefore, further studies should ascerta…”
Background
Cited by
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry
Shao, Y., Li, T., Liu, Z., Wang, X., Xu, X., Li, S., Xu, G., & Le, W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00425-8 · Cited by 226
“no associations with daily caffeine consumption [3, 71].”
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188
“Parkinson’s disease (PD) is a neurodegenerative disease with motor and non-motor symptoms [63].”
BackgroundMethodInfluentialThe Effect of Caffeine on the Risk and Progression of Parkinson’s Disease: A Meta-Analysis
Hong, C. T., Chan, L., & Bai, C.-H. (2020) · Nutrients · doi:10.3390/nu12061860 · Cited by 113
Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., et al. (2020) · Aging · doi:10.18632/aging.103992 · Cited by 50
ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
Siokas, V., Aloizou, A.-M., Tsouris, Z., Liampas, I., Liakos, P., Calina, D., Docea, A. O., Tsatsakis, A., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030381 · Cited by 29
Metadata
- Authors
- Fujimaki, M., Saiki, S., Li, Y., Kaga, N., Taka, H., Hatano, T., Ishikawa, K.-I., Oji, Y., Mori, A., Okuzumi, A., Koinuma, T., Ueno, S.-I., Imamichi, Y., Ueno, T., Miura, Y., Funayama, M., & Hattori, N.
- Venue
- Neurology
- Published
- 2018-01-30
- Volume
- 90
- Issue
- 5
- Pages
- e404-e411
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2782479110
- Cited by
- 100
- References
- 7
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000004888
- The paper
- Fujimaki, M., Saiki, S., Li, Y., Kaga, N., Taka, H., Hatano, T., Ishikawa, K.-I., Oji, Y., Mori, A., Okuzumi, A., Koinuma, T., Ueno, S.-I., Imamichi, Y., Ueno, T., Miura, Y., Funayama, M., & Hattori, N. (2018). Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. https://doi.org/10.1212/wnl.0000000000004888
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.